IONS241220C37500
- 0.70
- +0.30+75.00%
Ionis Pharmaceuticals Newsroom
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now
Here's Why Ionis Pharmaceuticals (IONS) Is Poised for a Turnaround After Losing -13.46% in 4 Weeks
Express News | Shares of Pharmaceutical and Healthcare Stocks Are Trading Lower. The Sector Has Been Under Pressure After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS
Catalyst Watch: Nvidia Earnings, Microsoft Ignite, Crypto Confidence, and P&G Event
Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer
Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $62
10 Health Care Stocks Whale Activity In Today's Session
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Lagging The Industry But So Is The Business
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $45 to $77
Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Ionis Pharmaceuticals: Promising Pipeline and Strategic Milestones Drive Buy Rating
Where Ionis Pharmaceuticals Stands With Analysts
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $51 to $77
Ionis to Present at Upcoming Investor Conferences
RBC Capital Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals Price Target Lowered to $77 From $82 at Wells Fargo
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT) and Cytokinetics (CYTK)
Ionis Pharmaceuticals (IONS) Gets a Hold From Barclays